共 50 条
- [11] Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol (vol 10, pg e46, 2023) LANCET HAEMATOLOGY, 2023, 10 (01): : E9 - E9
- [12] Lancet Diabetes Endocrinol (vol 11, pg 490, 2023) LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (10): : E12 - E12
- [13] Lancet Diabetes Endocrinol (vol 11, pg 905, 2023) LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : E1 - E1
- [14] Lancet Child Adolesc Health (vol 7, pg 379, 2023) LANCET CHILD & ADOLESCENT HEALTH, 2024, 8 (04): : e6 - e6
- [15] Lancet Infect Dis ( vol 23 , e520 , 2023 ) LANCET INFECTIOUS DISEASES, 2024, 24 (02): : e83 - e83
- [16] Correction to Lancet Neurol (vol 22, pg no 209-17, 2023) LANCET NEUROLOGY, 2023, 22 (08): : e9 - e9
- [17] Correction to Lancet Diabetes Endocrinol (Vol 10, pg 407, 2022) LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (08): : E8 - E8
- [19] Correction to Lancet Gastroenterol Hepatol (vol 8: pg 976-89,2023) LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : E8 - E8
- [20] Mechanism of hypoxia-induced NFκB (vol 10, pg 879, 2011) CELL CYCLE, 2011, 10 (12) : 2041 - 2041